Fayz Hudefi, MD
Addiction Medicine · Fort Smith, ARNPI 1992740393
Payments from drug & device makers
Across 1,139 payments — averaging $12,445 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$9.1M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1.6M
- E.r. Squibb & Sons, L.L.C.$1.2M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$785K
- AbbVie$757K
- Sage Therapeutics, LLC$208K
- plus $518K from 20 others
Across 20 payments — averaging $190.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Corcept Therapeutics$1K
What the payments were for
- Consulting fees$85041%
- Food & beverage$1,20159%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 183 | $9,096,044 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 542 | $1,624,195 |
| E.r. Squibb & Sons, L.L.C. | 9 | $1,186,627 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 19 | $784,616 |
| AbbVie(2 entities) | 76 | $757,261 |
| Sage Therapeutics, LLC | 53 | $207,696 |
| Biogen | 5 | $151,715 |
| Corcept Therapeutics | 57 | $142,615 |
| GW Research Limited | 18 | $68,324 |
| Alkermes, Inc. | 58 | $39,883 |
| Tolmar, Inc. | 6 | $30,574 |
| LEO Pharma AS | 7 | $26,962 |
| Novartis | 5 | $19,050 |
| Acadia Pharmaceuticals Inc | 66 | $14,383 |
| Genentech, Inc. | 5 | $9,906 |
| Eisai Inc. | 2 | $6,894 |
| Merck | 1 | $5,731 |
| Neurocrine Biosciences, Inc. | 11 | $1,557 |
| Johnson & Johnson | 2 | $147 |
| Sunovion Pharmaceuticals Inc. | 2 | $142 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Boehringer Ingelheim International GmbH | 2 | $83 |
| Neuronetics, Inc. | 1 | $68 |
| Vanda Pharmaceuticals Inc. | 4 | $58 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few addiction medicine providers in Arkansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $107,241 |
| Risperdal ConstaRisperidone Microspheres | 34 | $44,517 |
| Chlorpromazine Hcl | 120 | $43,488 |
| Divalproex Sodium ErDivalproex Sodium | 67 | $7,361 |
| Fluoxetine Hcl | 145 | $5,909 |
| Quetiapine Fumarate | 148 | $4,759 |
| Olanzapine OdtOlanzapine | 13 | $4,123 |
| Paliperidone ErPaliperidone | 19 | $3,543 |
| Risperidone | 145 | $2,659 |
| Haloperidol | 40 | $2,452 |
| Ziprasidone Hcl | 13 | $2,307 |
| Divalproex Sodium | 93 | $1,890 |
| Trazodone Hcl | 132 | $1,195 |
| Gabapentin | 69 | $1,143 |
| Atomoxetine Hcl | 13 | $1,043 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,557 | $107,24115 claims |
| Johnson & JohnsonRisperdal Consta | $147 | $44,51734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction medicine providers in Arkansason file to place this against a meaningful peer group, so we don't.
Other addiction medicine in Fort Smith
- Kristin MartinRussellville$11K
- Ronald OnlyJonesboro$760
- William WarrenLittle Rock$138
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.